阿立哌唑维持治疗老年精神分裂症42例临床分析

A clinical analysis of Aripiprazole in the maintenance treatment of Schizophrenia with late onset

目的：探讨阿立哌唑对老年精神分裂症患者长期治疗的临床疗效和安全性。方法：采用门诊开放性研究,对42例符合CCMD-3精神分裂症诊断标准的老年患者采用阿立哌唑5-20 mg/日治疗,以简明精神病评定量表（BPRS）评价临床有效性,用药物副反应量表（TESS）评价安全性,观察18个月。结果：有36例完成18个月的疗程,占85.71%（36/42）,BPRS减分率为73.5%,总有效率为83.33%。不良反应有便秘头晕乏力、失眠、静坐不能等,程度多为轻度和中度,未见严重的不良反应。结论：阿立哌唑能有效缓解老年精神分裂症的精神病性症状,安全性好,适合于门诊老年人的长期治疗。

Objective：To investigate the efficacy and safety of Aripiprazole in the treatment of schizophrenia patients with late onset in an 18 - month open trial. Methods：Forty - two patients in the study met the diagnostic critter is for schizophrenia described in the CCMD - 3. The dosage of Aripiprazole ranged 5 - 20 mg/day. The brief psychiatric rating scale （BPRS） was used for the efficacy and treatment emergent symptom scale （TESS） for unwanted effects. Results： Aripiprazole demonstrated overall response rate （73.5% decreases in the BPRS total score） and of the patients were rated as improvement. The main side effects of Aripiprazole were mild or middle extent of drowsiness, insomnia, akathisia and dizziness etc. Conclusions： Aripiprazole is safe and effective in the management of psychotic symptoms in old out patients with schizophrenia.